Find Lebrikizumab manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set

Drugs in Development

read-more
read-more

Details:

Ebglyss (lebrikizumab) is an approved high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 years of age and older with moderate-to-severe AD.


Lead Product(s): Lebrikizumab

Therapeutic Area: Dermatology Brand Name: LY3650150

Study Phase: Approved FDFProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 03, 2024

blank

01

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Details : Ebglyss (lebrikizumab) is an approved high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 years of age and older with moderate-to-severe AD.

Product Name : LY3650150

Product Type : Antibody

Upfront Cash : Inapplicable

October 03, 2024

blank

Details:

Ebglyss (lebrikizumab) is an approved high-affinity and potent IL-13 inhibitor approved for patients 12 years or older with moderate-to-severe Atopic Dermatitis.


Lead Product(s): Lebrikizumab

Therapeutic Area: Dermatology Brand Name: LY3650150

Study Phase: Approved FDFProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 13, 2024

blank

02

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Details : Ebglyss (lebrikizumab) is an approved high-affinity and potent IL-13 inhibitor approved for patients 12 years or older with moderate-to-severe Atopic Dermatitis.

Product Name : LY3650150

Product Type : Antibody

Upfront Cash : Inapplicable

September 13, 2024

blank

Details:

Ebglyss (lebrikizumab) is a monoclonal antibody that binds IL-13 with high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex. It is approved for the treatment of moderate-to-severe atopic dermatitis.


Lead Product(s): Lebrikizumab

Therapeutic Area: Dermatology Brand Name: Ebglyss

Study Phase: Approved FDFProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 17, 2023

blank

03

Almirall

Spain
arrow
EPS
Not Confirmed

Almirall

Spain
arrow
EPS
Not Confirmed

Details : Ebglyss (lebrikizumab) is a monoclonal antibody that binds IL-13 with high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex. It is approved for the treatment of moderate-to-severe atopic dermatitis.

Product Name : Ebglyss

Product Type : Antibody

Upfront Cash : Inapplicable

November 17, 2023

blank

Details:

Ebglyss (lebrikizumab) is an investigational, monoclonal antibody that binds IL-13, which is received positive CHMP opinion for moderate-to-severe atopic dermatitis.


Lead Product(s): Lebrikizumab

Therapeutic Area: Dermatology Brand Name: Ebglyss

Study Phase: Phase IIIProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 15, 2023

blank

04

Almirall

Spain
arrow
EPS
Not Confirmed

Almirall

Spain
arrow
EPS
Not Confirmed

Details : Ebglyss (lebrikizumab) is an investigational, monoclonal antibody that binds IL-13, which is received positive CHMP opinion for moderate-to-severe atopic dermatitis.

Product Name : Ebglyss

Product Type : Antibody

Upfront Cash : Inapplicable

September 15, 2023

blank

Details:

Ebglyss (lebrikizumab) is an investigational, monoclonal antibody that binds IL-13, and FDA has issued a complete response letter for the lebrikizumab biologic license application (BLA) for the treatment of moderate-to-severe atopic dermatitis (eczema).


Lead Product(s): Lebrikizumab

Therapeutic Area: Dermatology Brand Name: LY3650150

Study Phase: Phase IIIProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 10, 2023

blank

05

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Details : Ebglyss (lebrikizumab) is an investigational, monoclonal antibody that binds IL-13, and FDA has issued a complete response letter for the lebrikizumab biologic license application (BLA) for the treatment of moderate-to-severe atopic dermatitis (eczema).

Product Name : LY3650150

Product Type : Antibody

Upfront Cash : Inapplicable

February 10, 2023

blank

Details:

LY3650150 (lebrikizumab) is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 years of age and older with moderate-to-severe AD.


Lead Product(s): Lebrikizumab

Therapeutic Area: Dermatology Brand Name: LY3650150

Study Phase: Phase IIIProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 05, 2023

blank

06

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Details : LY3650150 (lebrikizumab) is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 years of age and older with moderate-to-severe AD.

Product Name : LY3650150

Product Type : Antibody

Upfront Cash : Inapplicable

January 05, 2023

blank

Details:

Lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the IL-13 protein with high affinity to specifically prevent the formation of IL-13Rα1/IL-4Rα (Type 2 receptor) which blocks downstream signaling through the IL-13 pathway.


Lead Product(s): Lebrikizumab,Undisclosed

Therapeutic Area: Dermatology Brand Name: LY3650150

Study Phase: Phase IIIProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 04, 2022

blank

07

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Details : Lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the IL-13 protein with high affinity to specifically prevent the formation of IL-13Rα1/IL-4Rα (Type 2 receptor) which blocks downstream signaling through the IL-13 pathway.

Product Name : LY3650150

Product Type : Antibody

Upfront Cash : Inapplicable

November 04, 2022

blank

Details:

New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity.


Lead Product(s): Lebrikizumab

Therapeutic Area: Dermatology Brand Name: LY3650150

Study Phase: Phase IIIProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 09, 2022

blank

08

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Details : New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity.

Product Name : LY3650150

Product Type : Antibody

Upfront Cash : Inapplicable

August 09, 2022

blank

Details:

Lebrikizumab (LY3650150), is a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling.


Lead Product(s): Lebrikizumab

Therapeutic Area: Dermatology Brand Name: LY3650150

Study Phase: Phase IIIProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 06, 2022

blank

09

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Details : Lebrikizumab (LY3650150), is a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling.

Product Name : LY3650150

Product Type : Antibody

Upfront Cash : Inapplicable

June 06, 2022

blank

Details:

More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75) at 16 weeks when receiving lebrikizumab, an investigational IL-13 inhibitor monotherapy.


Lead Product(s): Lebrikizumab

Therapeutic Area: Dermatology Brand Name: LY3650150

Study Phase: Phase IIIProduct Type: Antibody

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 26, 2022

blank

10

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Eli Lilly

U.S.A
arrow
EPS
Not Confirmed

Details : More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75) at 16 weeks when receiving lebrikizumab, an investigational IL-13 inhibitor monotherapy.

Product Name : LY3650150

Product Type : Antibody

Upfront Cash : Inapplicable

March 26, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

EPS
Not Confirmed
arrow
arrow
EPS
Not Confirmed

IDARUCIZUMAB

Brand Name : PRAXBIND

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 2.5G/50ML

Approval Date :

Application Number : 761025

RX/OTC/DISCN :

RLD :

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

EPS
Not Confirmed
arrow
arrow
EPS
Not Confirmed

Lebrikizumab

Brand Name : Ebglyss

Dosage Form : Solution for injection in a pre-filled pen

Dosage Strength : 250 mg

Packaging : Pre-filled pen 2 2ml

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

02

EPS
Not Confirmed
arrow
arrow
EPS
Not Confirmed

Lebrikizumab

Brand Name : Ebglyss

Dosage Form : Solution for injection, solution in pre-filled syringe

Dosage Strength : 250 mg

Packaging : Pre-filled syringe 2 2ml

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty